The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024: Featured Updates to the NCCN Guidelines
Open accessAbstract
The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic focus primarily on assessment of pathogenic/likely pathogenic (P/LP) variants associated with increased risk of breast, ovarian, pancreatic, and prostate cancer, including BRCA1, BRCA2, CDH1, PALB2, PTEN, and TP53, and recommended approaches to genetic counseling/testing and care strategies in individuals with these P/LP variants. These NCCN Guidelines Insights summarize important updates regarding: (1) a new section for transgender, nonbinary and gender diverse people who have a hereditary predisposition to cancer focused on risk reduction strategies for ovarian cancer, uterine cancer, prostate cancer, and breast cancer; and (2) testing criteria and management associated with TP53 P/LP variants and Li-Fraumeni syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Prediction of acute myeloid leukaemia risk in healthy individuals
Abelson, S., Collord, G., Ng, S. W. K., Weissbrod, O., Mendelson Cohen, N., Niemeyer, E., Barda, N., Zuzarte, P. C., Heisler, L., Sundaravadanam, Y., et al. (2018) · Nature · doi:10.1038/s41586-018-0317-6 · Cited by 850
The genomic landscape of hypodiploid acute lymphoblastic leukemia
Holmfeldt, L., Wei, L., Diaz-Flores, E., Walsh, M., Zhang, J., Ding, L., Payne-Turner, D., Churchman, M., Andersson, A., Chen, S.-C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2532 · Cited by 731
Villani, A., Shore, A., Wasserman, J. D., Stephens, D., Kim, R. H., Druker, H., Gallinger, B., Naumer, A., Kohlmann, W., Novokmet, A., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30249-2 · Cited by 546
Self-citationCancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome
Kratz, C. P., Achatz, M. I., Brugières, L., Frebourg, T., Garber, J. E., Greer, M.-L. C., Hansford, J. R., Janeway, K. A., Kohlmann, W. K., McGee, R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0408 · Cited by 534
Self-citationTrends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975‐2005
Ognjanovic, S., Linabery, A. M., Charbonneau, B., & Ross, J. A. (2009) · Cancer · doi:10.1002/cncr.24465 · Cited by 497
Villani, A., Tabori, U., Schiffman, J., Shlien, A., Beyene, J., Druker, H., Novokmet, A., Finlay, J., & Malkin, D. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70119-x · Cited by 423
TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade
Leroy, B., Anderson, M., & Soussi, T. (2014) · Human Mutation · doi:10.1002/humu.22552 · Cited by 408
de Blok, C. J. M., Wiepjes, C. M., Nota, N. M., van Engelen, K., Adank, M. A., Dreijerink, K. M. A., Barbé, E., Konings, I. R. H. M., & den Heijer, M. (2019) · BMJ · doi:10.1136/bmj.l1652 · Cited by 366
Li-Fraumeni syndrome – a molecular and clinical review
Varley, J., Evans, D., & Birch, J. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.328 · Cited by 358
Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers.
Nichols, K. E., Malkin, D. M., Garber, J. E., Fraumeni, J. F., & Li, F. P. (2001) · PubMed · Cited by 354
Sensitivity and predictive value of criteria for p53 germline mutation screening
CHOMPRET, A., ABEL, A., STOPPA-LYONNET, D., BRUGIÈRES, L., PAGÈS, S., FEUNTEUN, J., & BONAÏTI-PELLIÉ, C. (2001) · Journal of Medical Genetics · doi:10.1136/jmg.38.1.43 · Cited by 341
Follow-up study of twenty-four families with Li-Fraumeni syndrome.
Garber, J. E., Goldstein, A. M., Kantor, A. F., Dreyfus, M., Fraumeni, J. F., & Li, F. P. (1991) · PubMed · Cited by 275
Grynberg, M., Fanchin, R., Dubost, G., Colau, J.-C., Brémont-Weil, C., Frydman, R., & Ayoubi, J.-M. (2010) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2009.12.021 · Cited by 256
TP53 Alterations Determine Clinical Subgroups and Survival of Patients With Choroid Plexus Tumors
Tabori, U., Shlien, A., Baskin, B., Levitt, S., Ray, P., Alon, N., Hawkins, C., Bouffet, E., Pienkowska, M., Lafay-Cousin, L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.8169 · Cited by 247
Mandelker, D., Donoghue, M., Talukdar, S., Bandlamudi, C., Srinivasan, P., Vivek, M., Jezdic, S., Hanson, H., Snape, K., Kulkarni, A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz136 · Cited by 238
Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families
Bougeard, G., Sesboüé, R., Baert-Desurmont, S., Vasseur, S., Martin, C., Tinat, J., Brugières, L., Chompret, A., Paillerets, B. B.-D., Stoppa-Lyonnet, D., et al. (2008) · Journal of Medical Genetics · doi:10.1136/jmg.2008.057570 · Cited by 230
Birch, J. M., Blair, V., Kelsey, A. M., Evans, D. G., Harris, M., Tricker, K. J., & Varley, J. M. (1998) · Oncogene · doi:10.1038/sj.onc.1202033 · Cited by 200
BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives
Lalloo, F., Varley, J., Moran, A., Ellis, D., O’Dair, L., Pharoah, P., Antoniou, A., Hartley, R., Shenton, A., Seal, S., et al. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.11.032 · Cited by 175
Kuzbari, Z., Bandlamudi, C., Loveday, C., Garrett, A., Mehine, M. M., George, A. J., Hanson, H., Snape, K. M. G., Kulkarni, A., Allen, S., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.12.003 · Cited by 160
Gastric cancer in individuals with Li-Fraumeni syndrome
Masciari, S., Dewanwala, A., Stoffel, E. M., Lauwers, G. Y., Zheng, H. W., Achatz, M. I., Riegert‐Johnson, D. L., Foretová, L., da Silva, E. M., DiGianni, L. M., et al. (2011) · Genetics in Medicine · doi:10.1097/gim.0b013e31821628b6 · Cited by 148
de Andrade, K. C., Khincha, P. P., Hatton, J. N., Frone, M. N., Wegman-Ostrosky, T., Mai, P. L., Best, A. F., & Savage, S. A. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00580-5 · Cited by 135
Hu, C., Polley, E. C., Yadav, S., Lilyquist, J., Shimelis, H., Na, J., Hart, S. N., Goldgar, D. E., Shah, S. H., Pesaran, T. F., et al. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa023 · Cited by 124
Krutilkova, V., Trková, M., Fleitz, J. M., Gregor, V., Novotna, K., Křepelová, A., Sumerauer, D., Kodet, R., Širůčková, S., Plevová, P., et al. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.01.026 · Cited by 97
Thariat, J., Chevalier, F., Orbach, D. H., Ollivier, L., Marcy, P. Y., Corradini, N., Beddok, A., Foray, N., & Bougeard, G. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00425-3 · Cited by 94
Pediatric Cancer Predisposition Imaging: Focus on Whole-Body MRI
Greer, M. C., Voss, S. D., & States, L. J. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0515 · Cited by 92
Routine TP53 testing for breast cancer under age 30: ready for prime time?
McCuaig, J. M., Armel, S. R., Novokmet, A., Ginsburg, O., Demsky, R., Narod, S. A., & Malkin, D. M. (2012) · Familial Cancer · doi:10.1007/s10689-012-9557-z · Cited by 89
de Nie, I., de Blok, C. J. M., van der Sluis, T. M., Barbé, E., Pigot, G. L. S., Wiepjes, C. M., Nota, N. M., van Mello, N. M., Valkenburg, N. E., Huirne, J. A. F., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa412 · Cited by 89
Effects of Long-term Androgen Administration on Breast Tissue of Female-to-Male Transsexuals
Slagter, M. H., Gooren, L. J., Scorilas, A., Petraki, C. D., & Diamandis, E. P. (2006) · Journal of Histochemistry & Cytochemistry · doi:10.1369/jhc.6a6928.2006 · Cited by 84
Lee, D. S., Yoon, S., Looi, L., Kang, P. C. E., Kang, I. N., Sivanandan, K., Ariffin, H., Thong, M., Chin, K. F., Taib, N. A. M., et al. (2012) · Breast Cancer Research · doi:10.1186/bcr3172 · Cited by 67
Mai, P. L., Khincha, P. P., Loud, J. T., DeCastro, R. M., Bremer, R. C., Peters, J. A., Liu, C., Bluemke, D. A., Malayeri, A. A., & Savage, S. A. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.1350 · Cited by 65
Beyond Li-Fraumeni syndrome: Clinical characteristics of families with p53 germline mutations
Gonzalez, K. D., Noltner, K., Buzin, C. H., Gu, D., Wen-Fong, C. Y., Ngyuen, V. Q., Han, J. H., Lowstuter, K., Longmate, J., Sommer, S. S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.11031 · Cited by 58
Cohort study of cancer risk among insured transgender people
Silverberg, M. J., Nash, R., Becerra-Culqui, T. A., Cromwell, L., Getahun, D. T., Hunkeler, E. M., Lash, T. L., Millman, A. K., Quinn, V. P., Robinson, B. E., et al. (2017) · Annals of Epidemiology · doi:10.1016/j.annepidem.2017.07.007 · Cited by 55
Multiple Primary Cutaneous Melanomas in Li-Fraumeni Syndrome
Curiel‐Lewandrowski, C. N., Speetzen, L. S., Cranmer, L. D., et al. (2011) · Archives of Dermatology · doi:10.1001/archdermatol.2010.428 · Cited by 45
The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30
Ginsburg, O., Akbari, M. R., Aziz, Z., Young, R., Lynch, H. T., Ghadirian, P., Robidoux, A., Hernández, J. E. L., Vásquez, G., Gomes, M. C. B., et al. (2009) · Familial Cancer · doi:10.1007/s10689-009-9287-z · Cited by 40
Kappel, S., Janschek, E., Wolf, B., Rudas, M., Teleky, B. K., Jakesz, R., & Kandioler, D. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3424-1 · Cited by 33
Earlier Colorectal Cancer Screening May Be Necessary In Patients With Li-Fraumeni Syndrome
MacFarland, S. P., Zelley, K., Long, J. M., McKenna, D. B., Mamula, P., Domchek, S. M., Nathanson, K. L., Brodeur, G. M., Rustgi, A. K., Katona, B. W., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.09.036 · Cited by 30
Self-citationSutherland, N., Espinel, W., Grotzke, M. P., & Colonna, S. V. (2020) · Journal of Genetic Counseling · doi:10.1002/jgc4.1278 · Cited by 30
Shin, S. J., Dodd-Eaton, E. B., Gao, F., Bojadzieva, J., Chen, J., Kong, X., Amos, C. I., Ning, J., Strong, L. C., & Wang, W. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0725 · Cited by 19
Upper Gastrointestinal Cancer Risk and Surveillance Outcomes in Li-Fraumeni Syndrome
Katona, B. W., Powers, J. M., McKenna, D. B., Long, J. M., Le, A. N., Hausler, R. M., Zelley, K., Jennings, S., Domchek, S. M., Nathanson, K. L., et al. (2020) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000935 · Cited by 18
Self-citationSiegel, A., Bremer, R. C., Klein, W. M. P., Savage, S. A., Loud, J. T., & Khincha, P. P. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06410-5 · Cited by 18
Cited by
Caruso, G., Weroha, S. J., & Cliby, W. (2025) · JAMA · doi:10.1001/jama.2025.9495 · Cited by 304
Germline and somatic genomic testing for metastatic prostate cancer: ASCO guideline
Yu, E. Y., Rumble, R. B., Agarwal, N., Cheng, H. H., Eggener, S. E., Bitting, R. L., Beltran, H., Giri, V. N., Spratt, D., Mahal, B., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02608 · Cited by 64
Self-citationGermline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline Q and A
Kurian, A. W., Bedrosian, I., Kohlmann, W. K., Somerfield, M. R., & Robson, M. E. (2024) · JCO Oncology Practice · doi:10.1200/op.23.00771 · Cited by 8
Self-citation
Metadata
- Authors
- Daly, M. B., Pal, T., Maxwell, K. N., Churpek, J., Kohlmann, W., AlHilli, Z., Arun, B., Buys, S. S., Cheng, H., Domchek, S. M., Friedman, S., Giri, V., Goggins, M., Hagemann, A., Hendrix, A., Hutton, M. L., Karlan, B. Y., Kassem, N., Khan, S., Khoury, K., Kurian, A. W., Laronga, C., Mak, J. S., Mansour, J., McDonnell, K., Menendez, C. S., Merajver, S. D., Norquist, B. S., Offit, K., Rash, D., Reiser, G., Senter-Jamieson, L., Shannon, K. M., Visvanathan, K., Welborn, J., Wick, M. J., Wood, M., Yurgelun, M. B., Dwyer, M. A., & Darlow, S. D.
- Venue
- Journal of the National Comprehensive Cancer Network
- Publisher
- Harborside Press, LLC
- Published
- 2023-10
- Volume
- 21
- Issue
- 10
- Pages
- 1000-1010
- ISSN
- 1540-1405 (ISSN-L)
- 1540-1413
- OpenAlex
- W4387568247
- Cited by
- 315
- References
- 42
- FWCI
- 46.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.